These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
372 related articles for article (PubMed ID: 18484778)
1. Current perspectives on stability of protein drug products during formulation, fill and finish operations. Rathore N; Rajan RS Biotechnol Prog; 2008; 24(3):504-14. PubMed ID: 18484778 [TBL] [Abstract][Full Text] [Related]
3. Protein formulation and fill-finish operations. Patro SY; Freund E; Chang BS Biotechnol Annu Rev; 2002; 8():55-84. PubMed ID: 12436915 [TBL] [Abstract][Full Text] [Related]
4. Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients. Jorgensen L; Hostrup S; Moeller EH; Grohganz H Expert Opin Drug Deliv; 2009 Nov; 6(11):1219-30. PubMed ID: 19678792 [TBL] [Abstract][Full Text] [Related]
8. Primary packaging considerations in developing medicines for children: oral liquid and powder for constitution. Campbell GA; Vallejo E J Pharm Sci; 2015 Jan; 104(1):52-62. PubMed ID: 25393927 [TBL] [Abstract][Full Text] [Related]
9. The formulation and immunogenicity of therapeutic proteins: Product quality as a key factor. Richard J; Prang N IDrugs; 2010 Aug; 13(8):550-8. PubMed ID: 20721826 [TBL] [Abstract][Full Text] [Related]
10. Dosage form design and development. Allen LV Clin Ther; 2008 Nov; 30(11):2102-11. PubMed ID: 19108798 [TBL] [Abstract][Full Text] [Related]
11. Current good manufacturing practice regulations. Bumiller J Bull Parenter Drug Assoc; 1971; 25(5):222-5. PubMed ID: 5094094 [No Abstract] [Full Text] [Related]
12. Development of stable lyophilized protein drug products. Remmele RL; Krishnan S; Callahan WJ Curr Pharm Biotechnol; 2012 Mar; 13(3):471-96. PubMed ID: 22283723 [TBL] [Abstract][Full Text] [Related]
13. Effects of compounding and storage conditions on stability of pergolide mesylate. Davis JL; Kirk LM; Davidson GS; Papich MG J Am Vet Med Assoc; 2009 Feb; 234(3):385-9. PubMed ID: 19210262 [TBL] [Abstract][Full Text] [Related]
14. Cleaning characterization of protein drug products using UV-vis spectroscopy. Rathore N; Qi W; Ji W Biotechnol Prog; 2008; 24(3):684-90. PubMed ID: 18426244 [TBL] [Abstract][Full Text] [Related]
15. High throughput screening of protein formulation stability: practical considerations. Capelle MA; Gurny R; Arvinte T Eur J Pharm Biopharm; 2007 Feb; 65(2):131-48. PubMed ID: 17107777 [TBL] [Abstract][Full Text] [Related]
17. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design. Guenette E; Barrett A; Kraus D; Brody R; Harding L; Magee G Int J Pharm; 2009 Oct; 380(1-2):80-8. PubMed ID: 19596428 [TBL] [Abstract][Full Text] [Related]
18. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Cleland JL; Powell MF; Shire SJ Crit Rev Ther Drug Carrier Syst; 1993; 10(4):307-77. PubMed ID: 8124728 [TBL] [Abstract][Full Text] [Related]
19. Effects of surfaces and leachables on the stability of biopharmaceuticals. Bee JS; Randolph TW; Carpenter JF; Bishop SM; Dimitrova MN J Pharm Sci; 2011 Oct; 100(10):4158-70. PubMed ID: 21523787 [TBL] [Abstract][Full Text] [Related]
20. Impact of Freeze/Thaw Process on Drug Substance Storage of Therapeutics. Rayfield WJ; Kandula S; Khan H; Tugcu N J Pharm Sci; 2017 Aug; 106(8):1944-1951. PubMed ID: 28343990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]